File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1586/14737167.5.6.775
- Scopus: eid_2-s2.0-30344484840
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: The market for antituberculosis drugs and vaccines: Incentives for investment in new products
Title | The market for antituberculosis drugs and vaccines: Incentives for investment in new products |
---|---|
Authors | |
Keywords | BCG Directly observed therapy short course DOTS High-risk groups Immunization Market TB TB vaccine Tuberculosis |
Issue Date | 2005 |
Citation | Expert Review of Pharmacoeconomics and Outcomes Research, 2005, v. 5, n. 6, p. 775-781 How to Cite? |
Abstract | The market for antituberculosis drugs is reviewed briefly and an estimate is formed of the potential US market for a new and improved tuberculosis vaccine. By 2010, global sales of all antituberculosis drugs are expected to reach $US612-670 million annually. An urgent need for better antituberculosis drugs exists that could permit a shorter course and less frequent dosing so that tuberculosis treatment regimens could scale up more rapidly. Should a more effective tuberculosis vaccine become available, there are approximately 18 million high-risk individuals in the USA alone for whom the vaccine would be demonstrably cost-beneficial. The high-risk groups include healthcare workers, military personnel, HIV-infected individuals, migrant farm workers and prisoners. © 2005 Future Drugs Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/326701 |
ISSN | 2023 Impact Factor: 1.8 2023 SCImago Journal Rankings: 0.671 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chaudhry, Rochika G. | - |
dc.contributor.author | Bishai, David M. | - |
dc.date.accessioned | 2023-03-31T05:25:54Z | - |
dc.date.available | 2023-03-31T05:25:54Z | - |
dc.date.issued | 2005 | - |
dc.identifier.citation | Expert Review of Pharmacoeconomics and Outcomes Research, 2005, v. 5, n. 6, p. 775-781 | - |
dc.identifier.issn | 1473-7167 | - |
dc.identifier.uri | http://hdl.handle.net/10722/326701 | - |
dc.description.abstract | The market for antituberculosis drugs is reviewed briefly and an estimate is formed of the potential US market for a new and improved tuberculosis vaccine. By 2010, global sales of all antituberculosis drugs are expected to reach $US612-670 million annually. An urgent need for better antituberculosis drugs exists that could permit a shorter course and less frequent dosing so that tuberculosis treatment regimens could scale up more rapidly. Should a more effective tuberculosis vaccine become available, there are approximately 18 million high-risk individuals in the USA alone for whom the vaccine would be demonstrably cost-beneficial. The high-risk groups include healthcare workers, military personnel, HIV-infected individuals, migrant farm workers and prisoners. © 2005 Future Drugs Ltd. | - |
dc.language | eng | - |
dc.relation.ispartof | Expert Review of Pharmacoeconomics and Outcomes Research | - |
dc.subject | BCG | - |
dc.subject | Directly observed therapy short course | - |
dc.subject | DOTS | - |
dc.subject | High-risk groups | - |
dc.subject | Immunization | - |
dc.subject | Market | - |
dc.subject | TB | - |
dc.subject | TB vaccine | - |
dc.subject | Tuberculosis | - |
dc.title | The market for antituberculosis drugs and vaccines: Incentives for investment in new products | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1586/14737167.5.6.775 | - |
dc.identifier.scopus | eid_2-s2.0-30344484840 | - |
dc.identifier.volume | 5 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 775 | - |
dc.identifier.epage | 781 | - |
dc.identifier.eissn | 1744-8379 | - |